

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
30 September 2004 (30.09.2004)

PCT

(10) International Publication Number  
**WO 2004/083375 A2**

(51) International Patent Classification<sup>7</sup>: C12N  
(21) International Application Number: PCT/IT2004/000133  
(22) International Filing Date: 19 March 2004 (19.03.2004)  
(25) Filing Language: Italian  
(26) Publication Language: English  
(30) Priority Data:  
RM2003 A 000125 21 March 2003 (21.03.2003) IT  
RM2003A000370 29 July 2003 (29.07.2003) IT

(71) Applicants and  
(72) Inventors: MINCHIOTTI, Gabriella [IT/IT]; Via Ugo Ricci, 19, I-80100 Napoli (IT). PERSICO, Maria [IT/IT]; Via Camillo De Nardis, 10, I-80127 Napoli (IT). PARISI, Silvia [IT/IT]; Via Roma, 136, I-80027 Napoli (IT).

(74) Agents: CAPASSO, Olga et al.; De Simone & Partners S.p.A., Via Vincenzo Bellini, 20, I-00198 Roma (IT).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHOD OF PROMOTING THE DIFFERENTIATION OF STAMINAL CELLS

(57) Abstract: A method is described by which stem cells are induced to differentiate into cardiomyocytes; the method comprises exposure for a length of time and at efficacious quantities of a protein of the EGF-CFC family or its derivatives having at least the EGF and CFC domains; or to differentiate into neuronal cells, comprising the exposure to Cripto protein inhibitors. Compositions are described for therapeutic use in treating heart disorders, comprising a therapeutically efficacious quantity of a protein or its derivatives having at least the EGF and CFC domains of a protein of the EGF-CFC family.

Best Available Copy



WO 2004/083375 A2

## 5 METHOD FOR PROMOTING THE DIFFERENTIATION OF STAMINAL CELLS

\*\*\*\*\*

Field of the invention

10 The invention concerns a method to promote stem cell differentiation. In particular, the invention is a method that uses the Cripto protein or its analogues or functional derivatives or inhibitors to induce stem cell differentiation into different lineages, such as cardiomyocytes or neuronal cells. Within the scope of the invention, the stem cells comprise both embryonal stem (ES) cells and derivatives from nonembryonal tissues.

15 The EGF-CFC protein family (comprising Cripto, both human and mouse, chick, cryptic, oep, FRL-1 [Minchiotti et al., 2001] completely incorporated as reference) is involved in the embryonal development of vertebrates (Ding et al., 1998; Xu et al., 1999). Cripto is a molecular marker of undifferentiated ES cells in mice (Minchiotti et al., 2000) and human beings (Brivanlou et al., 2003).

Description of the invention

20 The authors of the present invention have investigated the role Cripto plays in modulating differentiation, particularly in cardiomyogenesis and in neuronal cell induction. The authors found that the timing of initiation and the duration of Cripto signaling are essential for inducing the differentiation of ES cells into cardiomyocytes, indicating that Cripto acts during an early phase. However, Cripto seems to inhibit  
25 differentiation to the neuronal lineage. The authors have also reported that Cripto induction activates an intracellular protein that acts as a transducer in extracellular signaling, Smad2 (Adamson et al., 2002), and that the overexpression of the activated forms of type I Alk4 receptor compensates for the lack of Cripto signaling. Both the EGF-CFC domains are necessary for cardiomyogenesis, whereas they inhibit neuronal  
30 differentiation.

The invention may be advantageously applied as a stimulator of stem cells for transplants in the treatment of degenerative diseases such as myocardial infarction (Min JY et al., 2002). As is known, the adult heart has a limited regeneration capacity, so that any significant cell loss, as occurs during extensive cardiac infarction, is irreversible and  
35 can lead to a progressive deterioration of heart function and the development of heart failure (Gepstein et al., 2002). Both human and mouse ES cells differentiate spontaneously *in vitro* into cardiomyocytes when an embryoid body (EB) technique is

Best Available Copy

applied; however, the specific biochemical stimuli for this process are unknown. Furthermore, cardiomyocytes represent only a minority of the EB cell population. The introduction of control genes in the development of stem cells represents an advantageous strategy to direct their differentiation, despite the various undesired side effects resulting from clonal variation, dependence on the primer and the ability of some stem cells to suppress the expression of ectopically transgenes expressed (Boehler et al., 2002).

The invention may be advantageously applied as a method to treat stem cells for use in transplants for neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, retinal degeneration, etc. Hence, ES cells constitute a nearly unlimited source of cells for cell therapy in treating degenerative diseases (Hynes and Rosenthal, 2000; Liu et al., 2000; Min et al., 2002; Svendsen and Smith, 1999). It is known, in fact, that ES cells can proliferate and differentiate in all types of an organism's cells. A recent report has indicated that ES cells are optimal candidates for cell therapy for neurodegenerative diseases since they can produce appropriate cell types when primed *in vivo* (Bjorklund et al., 2002; Arenas, 2002; Hara et al., 2004). In this context, it is crucial to develop experimental methods to prime cell differentiation starting with undifferentiated ES cells and then to demonstrate that the cells are effectively able to work as intended in treating a disease.

Previous studies showed that treating wild type ES cells with retinoic acid is able to prime neuronal differentiation (Bain et al., 1995). The limit to this study protocol is linked to the side effects retinoic acid carries; retinoic acid is a potent teratogenic agent that causes alterations in the development of the nervous system during embryogenesis *in vivo* (Soprano and Soprano, 1995; Sucov and Evans, 1995). Hence, it is crucially important to define alternative study protocols. One advantageous alternative strategy to direct cell differentiation includes the introduction of control genes in stem cells development, despite the undesired side effects resulting from clonal variance, dependence on the promoter and ability of some stem cells to suppress the expression of ectopically expressed transgenes (Boehler et al., 2002).

To overcome this problem, it is necessary to identify secreted molecule that can induce and/or inhibit stem cell differentiation toward a selected cell line.

Hence, the objective of the present invention is a method to induce stem cell differentiation into cardiomyocytes, wherein the cells are exposed for a period of time

and in efficacious quantities to a protein of the EGF-CFC family or its derivatives, which comprises at least the EGF-CFC domains. Preferably, the EGF and CFC domains derive from the sequence of the Cripto protein, more preferably the EGF and CFC domains derive from the sequence of human Cripto or the EGF and CFC domains  
5 derive from the sequence of mouse Cripto.

In an applied form, cell exposure occurs through genetic expression in stem cells via a suitable vector.

Another object of the invention is stem cells induced to differentiate into cardiomyocytes obtained with the described method.

10 A further object of the invention is a composition for the treatment of heart diseases that comprises stem cells treated according to the described method.

A further object of the invention is the use of the stem cells described for the treatment of heart diseases.

A further object of the invention is a composition for therapeutic use for treating heart  
15 disorders that comprises a therapeutically effective quantity of a protein or its derivative, having as a minimum the EGF and CFC domains of a protein of the EGF-CFC family. Preferably, the protein has at least the EGF and CFC domains of the Cripto protein. More preferably, the EGF and CFC domains derive from the human Cripto sequence or from the mouse Cripto sequence.

20 A further object of the invention is a method to induce stem cell differentiation into neuronal cells, wherein the cells are exposed for a period of time and in efficacious quantities to an inhibitor of the protein Cripto or the engineering of the cells in such a manner that they do not express endogenous functioning Cripto. Preferably, exposure to a Cripto inhibitor occurs in the early phases of stem cell differentiation.

25 Preferably, the inhibitor of Cripto is an anti-Cripto antibody or its functional fragments; alternatively, it is a peptide specifically selected from a random recombinant peptide library, alternatively it is an antagonist of the Alq4(receptor)-Cripto(co-receptor)-Nodal(ligand) pathway. Preferably, the antagonist is the peptide Cerberus or its functional derivatives.

30 A further object of the invention is stem cells induced to differentiate into neuronal cell lines obtained by the described method.

A further object of the invention is a composition for the treatment of neuropathologies that comprises the described stem cells.

A further object of the invention is the use of the described stem cells for treating neuropathologies.

A further object of the invention is the use of Cripto or its inhibitors in the preparation of a composition able to direct stem cell differentiation toward the neuronal lineage.

5 The present invention will now be described using non-restrictive examples in reference to the following figures:

Figure 1. Schematic representation of the experimental protocol used for ES cell differentiation into cardiomyocytes (adapted from Maltsev et al., 1993).

10 Figure 2. Functional dissection of Cripto. Schematic representation of *cripto* cDNA derivatives. EGF (Epidermal Growth Factor), CFC (Cripto, FrL1, Cripto) (Minchiotti et al., 2001), SP (signal peptide).

(A) Determination of minimal domains required for Cripto activity in cardiomyocyte differentiation. Both wt and deleted *cripto* mutant derivatives were transfected into Cripto<sup>-/-</sup> ES cells; empty vector was used as a control. The percentage of EBs with rhythmically contracting areas detectable by light microscopy was scored from days 15 8 to 12. Data are representative of at least two independent experiments.

(B) Western blot analysis of conditioned media from 293EBNA cells transfected with *cripto* cDNA deletion derivatives. Cells were cotransfected with *Plgf* expression vector as an internal control (see Materials and Methods). Lane 1: EGF-CFC; lane 2: 20 EGF long; lane 3: vector. The molecular mass of protein standards is indicated (kDa).

(C) Expression of cardiac specific genes MLC2v and  $\alpha$ MHC during *in vitro* differentiation of either wt or Cripto<sup>-/-</sup> ES cells. RT-PCR was performed on RNAs extracted from either undifferentiated ES cells or EBs over a 10-day differentiation 25 period (days 2 to 10). HPRT gene expression was analyzed as an internal control.

(D) RNA expression levels of MLC2v and cardiac  $\alpha$ MHC genes during *in vitro* differentiation of Cripto<sup>-/-</sup> ES cells overexpressing either wild type or *cripto* deletion mutants. RNA was harvested at days 5, 7 and 10 of the differentiation protocol and subjected to RT-PCR. Empty vector was used as a negative control. HPRT gene 30 expression was analyzed as an internal control. The results are representative of two independent differentiation programs.

Figure 3. Cripto expression profile during the *in vitro* differentiation of ES cells.

Total lysates of either undifferentiated ES cells or EBs at different days of differentiation (from 2 to 7 days), derived from either RI (wt) or DE7 (Cripto<sup>-/-</sup>) ES cells, were collected in lysis buffer and analyzed by Western blot using a polyclonal anti-Cripto antiserum (Minchiotti et al., 2000). Data were normalized to the expression level of Porin.

Figure 4. Dynamics of Cripto signaling during cardiomyocyte differentiation.

- a) Definition of the temporal activity of Cripto. Percentage of Cripto<sup>-/-</sup> EBs containing beating areas after the addition of recombinant Cripto protein. Ten µg/ml of soluble Cripto protein were added to EBs at 24-h intervals starting from time 0 of the *in vitro* differentiation assay (Figure 1). The number of EBs containing beating areas was scored from days 8 to 12 of *in vitro* differentiation.
  - b) Dose-dependent activity of Cripto protein. Two-day-old Cripto<sup>-/-</sup> EBs were treated with increasing amounts of recombinant soluble Cripto protein for 24 h, and then cultured for the remaining days. Appearance of beating areas was scored from days 8 to 12 of the *in vitro* differentiation.
  - c) Duration of Cripto signaling. Two-day-old Cripto<sup>-/-</sup> EBs were treated with 10 µg/ml of recombinant soluble Cripto protein for different lengths of time: 1h, 12h, 24h, and 3 days; EBs were then washed to remove the protein and cultured for the remaining days. Cells were examined for cardiac differentiation as described above.
- In all cases two independent Cripto<sup>-/-</sup> ES clones (DE7 and DE14) were used. Data are representative of at least two independent experiments.

Figure 5. Activation of Smad2 in Cripto<sup>-/-</sup> cell aggregates treated with recombinant Cripto protein.

Two-day-old Cripto<sup>-/-</sup> EBs were serum-starved for 3 h and then treated with 10 µg/ml of recombinant Cripto protein for 30, 60, 120 minutes or left untreated, as indicated. Smad2 activation was detected by Western blot analysis using anti-phospho-Smad2 antibody. Levels of total Smad2 were also compared.

Figure 6. Expression profile of Nodal, Alk4 and ActRIIB during cardiomyocyte differentiation and their effects on cardiac induction.

(A) RNA expression levels of Nodal, Alk4 and ActRIIB genes during *in vitro* differentiation of ES cells. RT-PCR analysis was performed on RNAs extracted from either undifferentiated ES or EBs (both wt and Cripto<sup>-/-</sup>) over a 10-day differentiation period (days 2 to 10). HPRT gene was used as an internal control.

(B) Western blot analysis of total lysates from 293EBNA cells transfected with either wild type (wt) or a constitutively activated (ca) form of HA-tagged human Alk4. Cells were cotransfected with Jun-HA expression vector as an internal control. A monoclonal anti-HA antibody was used to detect protein levels.

- 5 (C) RNA expression profile of the  $\alpha$ MHC gene during differentiation of *Cripto*<sup>-/-</sup> ES cells (days 5, 7 and 10) overexpressing wt and activated forms of either Alk4 or Taram-A. HPRT gene was used as an internal control.

Figure 7. Identification of *Cripto* key residues required for cardiac induction and differentiation.

- 10 Schematic representation of *Cripto* wt and mutant derivatives.

(A) Western blot analysis of total lysates from 293EBNA cells transfected with either wt or *cripto* mutant derivatives. Jun-HA expression vector was cotransfected as an internal control. Either polyclonal anti-*Cripto* or monoclonal anti-HA antibodies were used to detect protein levels.

- 15 (B) RNA expression levels of the cardiac  $\alpha$ MHC and MLC2v genes during *in vitro* differentiation of *Cripto*<sup>-/-</sup> ES cells (days 5, 7 and 10) overexpressing either wt or *cripto* mutant derivatives. Expression level of HPRT gene was analyzed as an internal control.

Figure 8. *Cripto* promotes cardiac differentiation and inhibits differentiation to neuronal ES cells.

- 20 (A) Cardiac and neuronal differentiation of *Cripto*<sup>-/-</sup> EBs as indicated by immunofluorescence assays. Two-day old *Cripto*<sup>-/-</sup> EBs were treated (b,d) or not (a,c) with 10  $\mu$ g/ml of soluble *Cripto* for 24 h. On day 12 of differentiation, expression of sarcomeric myosin and isotype III  $\beta$ -tubulin were analyzed using anti MF-20 antibodies (red: a,b) and isotype III anti  $\beta$ -tubulin (green: c,d), respectively.

- 25 (B) The percentage of *Cripto*<sup>-/-</sup> EBs positive to isotype III  $\beta$ -tubulin or MF-20. Ten  $\mu$ g/ml of soluble *Cripto* were added to the *Cripto*<sup>-/-</sup> EBs at 24-h intervals starting from time 0 of *in vitro* differentiation (cf. diagram in Figure 1). On day 12 of differentiation, the expression of isotype III  $\beta$ -tubulin and/or sarcomeric myosin were analyzed by immunofluorescence using isotype III  $\beta$ -tubulin antibodies and anti MF-20, respectively.
- 30

Materials and methods

### Plasmids and mutants

The beta-pallino A vector is derived from the pallino expression vector (courtesy of Dr. S. Chiocca) with the following modifications: the CMV promoter is excised as an EcoRI/ HindIII DNA fragment and replaced with a SalI/HindIII DNA fragment spanning the chicken  $\alpha$ -actin promoter followed by the 3' flanking sequence of the rabbit beta-globin gene (pCXN2 vector; Niwa et al., 1991). Other plasmid vectors may be used as long as the cDNA to be expressed is controlled by transcription promoter sequences and by stabilizer sequencers at 3' active in stem cells, like the  $\beta$ -actin promoter followed by the 3' flanking sequence of  $\beta$ -globin. Restriction sites were blunt-ended using Klenow polymerase. All the *cripto* mutant derivatives described (both deletions and amino acid substitutions) were obtained by the PCR-based method using the complete *cripto* cDNA and appropriate oligonucleotides, as previously described (Minchiotti et al., 2001). The cDNA Cripto-His (sequence from nt -5 to nt +468 of the cDNA *cripto*), here renamed "secreted Cripto", was cloned in the pCDNA3 expression vector (Invitrogen), as described elsewhere (Minchiotti et al., 2001). The cDNAs for *cripto* EGF long (sequence from nucleotide -5 to nucleotide +288 of *cripto* cDNA, Dono et al., 1993) and *cripto* EGF short (sequence from nucleotide -5 to +75 fused to nucleotides +157/+288 of *cripto* cDNA), wt and activated (ca) Alk4, wt and activated (ca) Taram-A, Cerberus and Cerberus S, were subcloned into beta-pallino A vector for expression in ES cells. When necessary, restriction sites were blunt-ended using Klenow polymerase.

### Cell cultures and ES differentiation

Human embryonic kidney 293 and 293EBNA cells (ATTC, CRL-1573) and 293T (ATCC, CRL-11268) were cultured in Dulbecco modified Eagle's medium (Celbio) supplemented with 10% fetal bovine serum (Euroclone), 50 U/ml of penicillin and 50 U/ml of streptomycin (GIBCO).

The ES cell lines RI (mouse wild type ES cells, Nagy et al., 1993) and *Cripto*<sup>-/-</sup>, DE7 and DE14, were used throughout the study. *Cripto*<sup>-/-</sup> DE7 and DE14 derive from transfection of two independent *Cripto*<sup>+/-</sup> ES clones (Xu et al., 1999). Wild type and *Cripto*<sup>-/-</sup> ES cells were maintained in the undifferentiated state by culture on mitomycin C-treated mouse embryonic fibroblast (MEF) feeder layers according to standard protocols. The medium used was high glucose Dulbecco's modified Eagle's medium (Celbio) containing 15% fetal bovine serum (Hyclone), 0.1 mM  $\beta$ -mercaptoethanol



(Sigma), 1 mM sodium pyruvate (GIBCO), 1X non essential aminoacids (GIBCO), 2 mM glutamine (GIBCO), 100U/ml penicillin/streptomycin (GIBCO) and  $10^3$  U/ml leukemia inhibitory factor (LIF) (Chemicon). For *in vitro* differentiation to cardiomyocytes, ES cells were cultivated in embryoid bodies essentially as described (Maltsev et al., 1993; Wobus et al. 1991). Briefly, 400 cells in 20  $\mu$ l culture medium without LIF (Leukemia Inhibitory Factor used to maintain the ES cells in an undifferentiated state) were placed on the lids of tissue culture dishes filled with PBS and cultivated in hanging drops for 2 days. After further 3 days of culture in bacteriological Petri dishes (Figure 1) in culture medium without LIF, the 5-day-old EBs were plated separately onto gelatin-coated 48-well plates for morphological analysis, onto 100 mm tissue culture plates for RT-PCR and Western blot. Rhythmic beating of the EBs, which indicates cardiac muscle differentiation, was monitored using phase microscopy (Leica).

#### Cell transfection and protein purification

Undifferentiated ES cells ( $10^7$ /ml) were electroporated with linearized DNA (30  $\mu$ g) at 400 V, 250  $\mu$ F in 0.9 ml of PBS. Pallino  $\beta$ A derivatives were digested with ScaI; nucleotide mutations were introduced by PCR to eliminate excess ScaI sites, when necessary. The electroporated cells were then plated onto puromycin-resistant STO cells (Smith and Hooper, 1983) in culture medium. Twenty four hours after plating, the medium was replaced with new medium containing 2  $\mu$ g/ml puromycin and the selection medium was changed every day. At day 7 after electroporation, resistant clones were pooled, expanded and subjected to the differentiation assay. Transfection of 293EBNA cell was performed as previously described (Minchiotti et al., 2000). Transfection efficiency was monitored by cotransfection with a cDNA encoding the Placenta growth factor (Plgf; Maglione et al., 1991).

Recombinant secreted Cripto protein previously named Cripto-His was obtained and purified as previously described (Minchiotti et al., 2001). In brief, the protein was purified from the medium conditioned by a stably transfected clone of 293 cells obtained with the cripto-His pCDNA3 vector (Minchiotti, et al., 2001) using the Qiaexpress protein purification system (Quiagen). The purified protein was dialyzed against 50 mM sodium phosphate buffer, pH 8. The recombinant Cripto-Fc protein was purified from the medium conditioned by 293T cells transfected with the CriptoFc/pIg vector according to the manufacturer's instructions (R&D).

### Western blotting and Smad2 induction

Undifferentiated (wt or Cripto<sup>-/-</sup>) ES cells or EBs derived from either wt (RI) or Cripto<sup>-/-</sup> (DE7) ES cell lines at different stages during *in vitro* differentiation were lysed in a buffer containing: 10mM Tris/Cl pH 8, 140mM NaCl, 2mM EDTA pH 8, 1% NP-40 and analyzed by Western blot as previously described (Minchiotti et al., 2000). The anti-HA (12CA5) monoclonal antibody (ROCHE) and anti-Porin 31HL antibody (Calbiochem, cat. #529538) were used according to manufacturer's instructions.

Two-day-old Cripto<sup>-/-</sup> EBs were starved for 3 h in medium without LIF and in low serum (1%), after which Cripto-His protein was added directly to the same medium. At the indicated time, EBs were dissolved in Laemmli lysis buffer (Laemmli, 1970) and analyzed by Western blot using the Trans-Blot Semi-dry System (BIO-RAD), following manufacturer's instructions. Rabbit polyclonal anti-Smad2/3, anti-phospho-Smad2 (Ser465/467) (Upstate Biotechnology) and anti-phospho-ERK (Santa Cruz Biotechnology, Inc.) antibodies were used following the manufacturer's instructions.

### RNA preparation and RT-PCR

Total RNA from either undifferentiated ES cells or EBs from different stages of *in vitro* differentiation was extracted with TRIzol kit (Life Technologies Inc.) according to manufacturer's instructions and reverse transcribed to cDNA with SuperScript II reverse transcriptase (Life Technologies Inc.) and random hexamers (as primers). cDNA samples synthesized from 100ng of total RNA were subjected to PCR amplification with specific primers. The primers and the PCR conditions used were as follows:

Nodal: F, 5'TTCCTTCTCAGGTCACGTTTGC3';

R, 5'GGTGGGGTTGGTATCGTTTCA3,

annealing temperature: 58°C, cycles: 35, 518 bp fragment;

ALK-4: F, 5'AAGGATCCAGGCTCTGCTGTGTGCC3';

R, 5'ACGGATCCATGTCCAACCTCTGGCGG3',

annealing temperature: 60°C, cycles: 30, 411 bp fragment;

ActRIIB: F, 5'ATGTGCCGTGGTGTCGTGGT3'

R, 5'GACCTCCTGATCAGGGATAC,

annealing temperature: 58°C, cycles: 30, 541 bp fragment;

MLC2v: F, 5'GCCAAGAAGCGGATAGAAGGCGGG3';

R, 5'CTGTGGTTCAGGGCTCAGTCCTTC3';

annealing temperature: 70°C, cycles: 33, 490 bp fragment;

cardiac  $\alpha$ MHC : F, 5'GGAAGAGTGAGCGGCGCATCAAGG3'  
R, 5'CTGCTGGAGAGGTTATTCCTCG3',

annealing temperature: 65°C, cycles: 30, 301 bp fragment;

HPRT: F, 5'CCTGCTGGATTACATTAAAGCACTG3'

5 R, 5'CCTGAAGTACTCATTATAGTCAAGG3',

annealing temperature: 58°C, cycles: 25, 369 bp fragment; used as control.

#### Cripto mutant derivatives

All cripto mutants (both deletion and substitution) were obtained using a PCR-based method with complete Cripto cDNA as described (Minchiotti et al., 2001); in all cases  
10 the amplified fragments were sequenced in both directions with the dideoxy nucleotide procedure.

#### A. Deletion mutants

cDNA Cripto-His (sequence from nt -5 to nt +468 of cripto cDNA) was cloned in the pCDNA3 expression vector (Invitrogen) or into  $\beta$  pallino. The cDNA Cripto-FC  
15 (sequence from nt -5 to nt +468 of cripto cDNA) was produced using the pIg-tail expression system (N. MBK-006-5, R&D). Both the cDNA have been previously described elsewhere (Minchiotti et al., Development, 2001:4501—4510).

#### B. Point mutants

The cDNA cripto derivatives were obtained using the following nucleotides:

##### 20 1. Asn63-Ile

5'-GTAAGTCGCTTATTA AAACTTGCTGTC-3'

5'-GACAGCAAGTTT TAATAAGCGACTTAC-3'

##### 2. Gly71-Asn

5'-CTTGCTGTCTGAATGGAAACACTTGCATCCTGGGGTCC-3'

25 5'-GGACCC CAGGATGCAAGTGTTTCCATTCAGACAGCAAG-3'

##### 3. Thr72-Ala

5'-GAATGGAGGGGCTTGCATCCTGG-3'

5'-CCAGGATGCAAGCCCCTCCATTC-3'

##### 4. Ser77-Ala

30 5'-CTTGCATCCTGGGGGCCTTCTGTGCCTGC-3'

5'-GCAGGCACAGAAGGCCCCCAGGATGCAAG-3'

##### 5. Phe78-Ala

5'-GCATCCTGGGGTCCGCCTGTGCCTGCCCTCC-3'

5'-GCATCCTGGGGTCCGCCTGTGCCTGCCCTCC-3'

**6. Phe78-Trp**

5'-GCATCCTGGGGTCCTGGTGTGCCTGCCCTCC-3'

5'-GGAGGGCAGGCACACCAGGACCCCAGGATGC-3'

**5 7. His104-Ala**

5'-GTGGGTCTATCCTCGCTGGCACCTGGCTGCCC-3'

5'-GGGCAGCCAGGTGCCAGCGAGGATAGACCCAC-3'

**8. Trp107-Gly**

5'-CATGGCACCGGGCTGCCCAAG-3'

10 5'-CTTGGGCAGCCCGGTGCCATG-3'

**9. Arg116-Ala**

5'-GTGTTCCCTGTGCGCATGCTGGCACGGCCAG-3'

5'-CTGGCCGTGCCAGCATGCGCACAGGGAACAC-3'

**10. Leu122-Asn**

15 5'-GCTGGCACGGCCAGAACCACTGTCTTCCTCAG-3'

5'-CTGAGGAAGACAGTGGTTCTGGCCGTGCCAGC-3'

The cDNAs for Alk4 WT and activated (CA), Taram-A WT and activated (CA), activated smad2 (smad2CA) and activated Ras (RasCA) were subcloned into pallino  $\beta$ A for expression in ES cells. When necessary, the restriction sites were blunt-ended by Klenow polymerase.

The following protein sequences were obtained:

**mCripto**

MGYFSSSVVLLVAISSAFEFGPVAGRDLAIRDNSIWDQKEPAVRDRSFQFVPSV  
GIQNSKSLNKTCCLNNGGTCILGSFCACPPSFYGRNCEHDVRKEHCGSILHGTWL  
25 PKKCSLCRCWHGQLHCLPQTFLPGCDGHVMDQDLKASRTPCQTPSVTTTFMLA  
GACLFMDMKV

Nucleotides from -5 to +516 (Dono et al., 1993)

Amino acids 1-171 (Dono et al., 1993)

**Secreted (mCripto)**

30 MGYFSSSVVLLVAISSAFEFGPVAGRDLAIRDNSIWDQKEPAVRDRSFQFVPSV  
GIQNSKSLNKTCCLNNGGTCILGSFCACPPSFYGRNCEHDVRKEHCGSILHGTWL  
PKKCSLCRCWHGQLHCLPQTFLPGCDGHVMDQDLKASRTPCQTPSVTT

Nucleotides from -5 to +468 of the Cripto sequence (Dono et al., 1993)

Amino acids 1-156 of the Cripto sequence (Dono et al., 1993)

**Secreted His-tagged (mCripto His)**

MGYFSSSVVLLVAISSAFEFGPVAGRDLAIRDNSIWDQKEPAVRDRSFQFVPSV  
GIQNSKSLNKTCCLNNGGTCILGSFCACPPSFYGRNCEHDVRKEHCGSILHGTWL  
5 PKKCSLCRCWHGQLHCLPQTFLPGCDGHVMDQDLKASRTPCQTPSVTTTNSGH  
HHHHH

Nucleotides from -5 to +468 of the Cripto sequence (Dono et al., 1993)

Amino acids 1-156 of the Cripto sequence (Dono et al., 1993)

Amino acids 157-166 His-tag

10 **EGF-CFC (mCripto)**

MGYFSSSVVLLVAISSAFEFGPVAGSVGIQNSKSLNKTCCLNNGGTCILGSFCACP  
PSFYGRNCEHDVRKEHCGSILHGTWLPKKCSLCRCWHGQLHCLPQTFLPGCDG  
HVMDQDLKASRTPCQTPSVTT

15 Nucleotides from -5 to +75 fused to +157 at +468 of the mouse Cripto sequence (Dono et al., 1993)

Amino acids 1-25 fused to 53-156

**EGF-CFC His-tagged (mCripto)**

MGYFSSSVVLLVAISSAFEFGPVAGSVGIQNSKSLNKTCCLNNGGTCILGSFCACP  
PSFYGRNCEHDVRKEHCGSILHGTWLPKKCSLCRCWHGQLHCLPQTFLPGCDG  
20 HVMDQDLKASRTPCQTPSVTTTNSGHHHHHHH

Nucleotides from -5 to +75 fused at +157 at +468 of the mouse Cripto sequence (Dono et al., 1993)

Amino acids 1-25 fused at 53-156

Amino acids 157-166 His-tag

25 **EGF short (mCripto)**

MGYFSSSVVLLVAISSAFEFGPVAGSVGIQNSKSLNKTCCLNNGGTCILGSFCACP  
PSFYGRNCEHDVRK

Nucleotides from -5 to +75 fused at +157 at +288 (Dono et al., 1993)

Amino acids 1-25 fused at 53-96

30 **EGF long (mCripto)**

MGYFSSSVVLLVAISSAFEFGPVAGRDLAIRDNSIWDQKEPAVRDRSFQFVPSV  
GIQNSKSLNKTCCLNNGGTCILGSFCACPPSFYGRNCEHDVRK

Nucleotides from -5 to +288 of the mouse Cripto sequence (Dono et al., 1993)

Amino acids 1-96 (Dono et al., 1993)

**hCripto**

MDCRKMARFSYSVTWIMAISKVFELGLVAGLGHQEFARPSRGYLAFRDDSIWP  
 QEEPAIRPRSSQRVPPMGIQHSEKLNRTCCLNNGGTCMLGSFCACPPSFYGRNCE  
 5 HDVRKENCGSVPHDTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLV  
 ASRTPPELPPSARTTTFMLVGACFLDMKV

Nucleotides from 244 to 814 of the human Cripto sequence (Ciccodicola et al. 1989).

Amino acids 1-188 (Dono et al., 1993)

**hCripto secreted**

10 MDCRKMARFSYSVTWIMAISKVFELGLVAGLGHQEFARPSRGYLAFRDDSIWP  
 QEEPAIRPRSSQRVPPMGIQHSEKLNRTCCLNNGGTCMLGSFCACPPSFYGRNCE  
 HDVRKENCGSVPHDTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLV  
 ASRTPPELPPSARTT

Nucleotides from 244 to 766 of the human Cripto sequence (Ciccodicola et al., 1989).

15 Amino acids 1-173 (Dono et al., 1993)

**hCripto secreted his-tagged**

MDCRKMARFSYSVTWIMAISKVFELGLVAGLGHQEFARPSRGYLAFRDDSIWP  
 QEEPAIRPRSSQRVPPMGIQHSEKLNRTCCLNNGGTCMLGSFCACPPSFYGRNCE  
 HDVRKENCGSVPHDTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLV  
 20 ASRTPPELPPSARTTTNSGHHHHHH

Nucleotides from 244 to 766 of the human Cripto sequence

Amino acids 1-173 (Dono et al., 1993)

Amino acids 174-183 His tag

Immunofluorescence on EB

25 The EB were grown in adhesion. On day 12 of differentiation, they were fixed for 30 minutes at room temperature in a solution of 4% paraformaldehyde for treatment with isotype III  $\beta$ -tubulin antibody (Sigma) or on ice in a solution of methanol: acetone at a ratio of 7: 3 for treatment with anti-sarcomeric myosin MF-20 (Developmental Studies Hybridoma Bank, University of Iowa, Dept. of Biological Sciences, Iowa City, USA).

30 After 3 washings with phosphate buffer (PBS, GIBCO cat no. 20012-019), the EB were treated with 0.1% Triton X-100 (Sigma), 10% pre-immune goat serum (DAKO, code no. X0907) in PBS and then incubated with their respective primary antibodies in a 10% solution of pre-immune goat serum in PBS for 2 h at room temperature. The primary

antibody dilutions were: isotype III anti  $\beta$ - tubulin (1: 400), MF-20 (1: 50). The EBs were then washed with PBS and incubated at room temperature for 30 minutes in a 10% solution of pre-immune goat serum in PBS in the presence of the following secondary antibodies: mouse anti-antibody produced in goat and conjugated with rodamine (Jackson Laboratories, primary antibody MF-20) and mouse anti-antibody produced in goat and conjugated with fluorescein (Jackson Laboratories, primary antibody isotype III anti  $\beta$ -tubulin). The EBs were then thoroughly washed in PBS and counterstained with DAPI (4',6-diamidino-2-phenylindole hydrochloride, SIGMA) to visualize the nuclei. Lastly, the EBs were mounted using a Vecta Shield (Vector Laboratories, Burlingame, CA, USA) for epifluorescent light microscopy. The images were acquired using an Axiocam ARC system (Zeiss).

## Results

### Secreted Cripto retains its ability to rescue cardiomyocyte differentiation

Previous data on cultured ES cells lacking *cripto* have revealed an essential role of *cripto* for contractile cardiomyocyte formation. Cripto<sup>-/-</sup> ES cells selectively lose the ability to form beating cardiomyocytes, a process that can be rescued by expression of Cripto (Xu et al., 1998). However, it is highly advantageous to determine whether a secreted form of Cripto can restore cardiomyocyte differentiation in Cripto<sup>-/-</sup> ES cells. To this end, we overexpressed a secreted derivative of Cripto lacking the hydrophobic C-terminus region required for membrane anchorage (Minchiotti et al., 2000) in Cripto<sup>-/-</sup> ES cells and compared its activity to that of wt Cripto. A pooled population of cells selected for resistance to puromycin was examined for the number of EBs containing beating areas from days 8 to 12 of *in vitro* differentiation (Figures 1, 2A). Spontaneous rhythmic contractile myocytes were observed in Cripto<sup>-/-</sup> ES cells expressing either the membrane-anchored or the secreted Cripto protein (Figure 2B). Moreover, similar results were obtained by expressing a secreted Cripto protein which lacks the N-terminus region (EGF-CFC; Figures 2A and 2B), thus indicating not only that membrane anchorage is dispensable for activity, but also that the EGF-CFC domain alone is sufficient for Cripto activity in cardiogenic induction. It was then necessary to define whether the Cripto EGF-like domain alone was able to induce cardiogenesis similar to the EGF-CFC peptide. Two *cripto* cDNA deletion derivatives encoding either the EGF-like domain retaining the N-terminus region (EGF long) or just the EGF domain (EGF short, Figure 2A) were generated. No beating areas cells were observed in

EBs derived from Cripto<sup>-/-</sup> ES cells expressing either the EGF long or the EGF short peptide (Figure 2B), thus indicating that at least the CFC domain of Cripto is essential for cardiogenic induction. Western blot analysis showed that the EGF long peptide was produced and secreted as efficiently as EGF-CFC (Figure 2C), thus demonstrating that its inability to rescue the mutant phenotype is not due to a difference at the protein expression level. Similar results were obtained with the EGF short construct. To support the morphological data observed, we examined the expression of the cardiac-specific myosin heavy chain ( $\alpha$ MHC) and myosin light chain 2v (MLC2v), two major contractile proteins of cardiomyocytes. As expected, expression of the  $\alpha$ MHC and MLC2v genes was induced in wt ES cells but not in Cripto<sup>-/-</sup> cells from day 7 of *in vitro* differentiation (Figure 2D). The expression pattern of  $\alpha$ MHC and MLC2v genes in wt ES cells was reproduced in Cripto<sup>-/-</sup> cells expressing both wt Cripto and the secreted derivative, but not in cells expressing the EGF long or the EGF short peptides (Figure 2E).

#### Timing and duration of Cripto activity in cardiomyocyte differentiation

The timing of Cripto expression during ES cell differentiation was examined. Western blot analysis performed with anti-Cripto antibodies on lysates from both wt and Cripto<sup>-/-</sup> ES cells revealed that Cripto was detectable as early as day 0 and peaked in expression by day 4 in wt EBs (Figure 3). The transient nature of Cripto accumulation suggests that its activity might be required at a defined step in cardiomyocyte differentiation. Since transfection assays do not adequately investigate the window of Cripto action, a recombinant soluble Cripto protein was used in which the hydrophobic C-terminus was replaced with a 6xHis epitope (Cripto-His; Minchiotti et al., 2001). Based on the observation that secreted Cripto protein is able to promote cardiogenesis when expressed in the Cripto<sup>-/-</sup> ES cells (Figure 2B), experiments were performed where Cripto signaling was reconstituted by adding recombinant secreted Cripto protein directly to the cells (Figure 4). The addition of Cripto during the 0-2 day interval effectively restores the differentiation ability of Cripto<sup>-/-</sup> ES cells. Addition at later time points results in dramatically reduced cardiomyocyte differentiation (Figure 4A). Comparable results were obtained with two independent Cripto<sup>-/-</sup> ES clones (DE7 and DE14; Xu et al., 1998), thus excluding any phenotype difference due to clonal variation (Figure 4A). Taken together, these data indicate that stimulation *in trans* with soluble Cripto protein is fully efficient in promoting cardiomyocyte induction and



differentiation and, more interestingly, the data define exactly when Cripto activity is required to promote specification of the cardiac lineage. Furthermore, to define optimal concentrations of Cripto required to promote cardiogenesis, increasing amounts of purified recombinant Cripto protein were added directly to the culture medium of 2-day-old Cripto<sup>-/-</sup> EBs from either DE7 or DE14 cell lines for 24 h (Figure 4B). Increasing amounts of recombinant Cripto enhance differentiation efficiency (Figure 4B), thus indicating that Cripto-mediated cardiogenic induction is dose-dependent.

We then wanted to define whether the duration of Cripto signaling was crucial for its biological response. Two-day-old EBs from DE7 or DE14 Cripto<sup>-/-</sup> ES cells were treated with 10 µg/ml of recombinant Cripto for various lengths of time, washed to remove unbound Cripto, and then cultured for the remaining days. An effective Cripto response requires a minimum induction of 24 h, while shorter inductions show markedly reduced activity (Figure 4C). Taken together, our data demonstrate that the amount, timing and duration of Cripto signaling are all crucial factors for achieving cardiogenic induction and differentiation.

#### Cripto activates a Smad2 pathway associated with cardiomyocyte differentiation

Findings in mice, *Xenopus* and *Zebrafish* point to a strong functional link between the EGF-CFC proteins and Transforming Growth Factor alpha (TGFα)-ligand (Adamson et al., 2002; Shen and Schier, 2000). Accordingly, recent studies have shown that Cripto can associate with type I receptor ActRIIB (Alk4) and can form a complex together with Nodal and type II receptor ActRIIB (Reissman et al., 2001; Yeo and Whitman, 2001, Bianco et al., 2002; Yan et al., 2002). Activation of a Smad protein by phosphorylation is a universal signal transduction event following activation of Alk receptors. To determine whether Cripto activates the Smad2 pathway during cardiomyocyte induction and differentiation, 2-day-old Cripto<sup>-/-</sup> EBs were starved in low serum for 3 h and then stimulated with recombinant soluble Cripto protein for 30, 60 or 120 minutes. Western blot analysis revealed that phosphorylation of Smad2 significantly increases after treatment with recombinant Cripto. Smad2 phosphorylation was detectable already after 30 minutes of treatment and persisted at comparable levels even after prolonged exposure to Cripto protein. An anti Smad-2-3 antibody applied to the same blot was used to normalize for total amount of protein (Figure 5). *In vitro* studies on mammalian cell lines have suggested that Cripto is involved in the Ras/Raf/MEK/MAPK pathway (Salomon et al., 1999). The search for activation of the MAP kinase ERK by using an

anti-phospho-ERK antibody revealed that recombinant Cripto was unable to activate MAP kinase, thus indicating that the Smad2 pathway is selectively activated during cardiomyocyte induction and differentiation induced by Cripto.

Since no data are available on the expression profile of all components of the

5 Alk4/ActRIIB/Nodal complex during the differentiation of ES cells, we first measured by RT-PCR the expression of Nodal, Alk4 and ActRIIB in EBs derived from both wt and Cripto<sup>-/-</sup> ES cells. Nodal, Alk4 and ActRIIB were expressed in all analyzed stages (Figure 6A). If Cripto signaling in cardiomyocyte differentiation acts via the Alk4 receptor, overexpression of a constitutively active type I receptor would be expected to  
10 compensate for the lack of Cripto signaling in promoting cardiomyocyte differentiation.

To this end, we overexpressed in Cripto<sup>-/-</sup> ES cells the wild type (wt) or the activated form (ca) of both human HA-tagged Alk4 and its *Zebrafish* counterpart Taram-A (Renucci et al., 1996). Type I receptor serine/threonine kinases can be activated in a

ligand- and type II receptor-independent manner by replacing an acidic residue with a  
15 specific threonine within the juxtamembrane region of the intracellular domain, a segment known to be involved in kinase regulation (Wieser et al., 1995).

Overexpression of either Alk4 ca or Taram-A ca partially restores the ability of Cripto<sup>-/-</sup> ES cells to differentiate into cardiomyocytes (Table 1). In contrast, overexpression of the wt receptors, both Taram-A and Alk4, have no significant activity despite their  
20 similar expression levels (Figure 6B). In accordance with the morphological data, expression of the alphaMHC gene was only detected in Cripto<sup>-/-</sup> ES cells expressing the activated form of the receptors (Figure 6C).

Recent data in *Zebrafish* have shown that intracellular activation of the Nodal pathway, induced by expression of an activated form of the Taram-A receptor, is sufficient to

25 commit cells to an endodermal fate and behavior (David and Rosa, 2001). To exclude the possibility that activated Alk4 may interfere in this way with cardiomyocyte specification, recombinant Cripto was added to Alk4 ca expressing cells. Cripto treatment fully restores differentiation, indicating that the activated receptor has no inherent adverse effect on cardiomyocyte specification (Table 2).

30 Analysis of Cripto mutants identifies key residues in both the EGF and the CFC domains

As demonstrated, the EGF-CFC domain is sufficient to promote cardiogenic induction when overexpressed in Cripto<sup>-/-</sup> ES cells, whereas the EGF domain alone is unable to

rescue such biological activity. To determine the contribution of the EGF and the CFC domains, single amino acid substitutions were introduced in the *cripto* cDNA (Figure 7A) and the activity of the corresponding mutant proteins was compared with the wt in the cardiomyocyte assay. While each mutant was expressed at levels comparable with wt Cripto (Figure 7B), three of them were completely inactive or showed a strongly reduced activity (Table 3). Similar results were obtained with two independent Cripto<sup>-/-</sup> ES clones (Table 3). To support the observed morphological data, the expression of the  $\alpha$ MHC and the MLC2v genes was examined by RT-PCR on total RNA prepared from EBs derived from Cripto<sup>-/-</sup> ES cells overexpressing Cripto mutant derivatives (Figure 7C). Expression of  $\alpha$ MHC and MLC2v genes was either absent or reduced in cells overexpressing G71N, F78A or W107G *cripto* mutants, whereas it was restored in Cripto<sup>-/-</sup> cells transfected with wt *cripto*. Taken together, these data show that critical amino acid residues are located both in the EGF and in the CFC domains, thus indicating that both EGF and CFC domains are required for Cripto activity in cardiogenic induction.

Recent reports have shown that Cripto is modified by the addition of sugar residues. N-linked glycosylation was shown to affect Cripto biological activity in the *Zebrafish* assay (Minchiotti et al., 2001). More recently, an O-linked fucosylation of Cripto has been reported to be required for Cripto signaling activity in cotransfection assay in mammalian cells (Schiffer et al., 2001; Yan et al., 2002). To assess whether post-translational modifications are required for Cripto activity in cardiogenic induction, two alanine substitutions were generated, corresponding to the N-glycosylation site (N63I) and the O-linked fucosylation site (T72A). The activities of the corresponding mutant proteins were tested in the differentiation assay and compared with wt Cripto. Based on the percentage of EBs containing beating areas, both mutant proteins have a similar ability to promote cardiomyocyte differentiation in comparison with wt Cripto (Table 3), thus suggesting that the addition of sugar residues is not strictly required for Cripto activity in ES cells.

---

Table 1. Percentage of beating EBs from Cripto<sup>-/-</sup> ES cells transfected with either the wild type or the constitutively activated form of human Alk4 or *Zebrafish* Taram-A receptors.

| Cells | Construct    | EBs scored | % of beating EB |
|-------|--------------|------------|-----------------|
| DE7   | None         | 70         | 0               |
| DE7   | Cripto wt    | 50         | 96.6            |
| DE7   | Alk4 wt      | 76         | 0               |
| DE7   | Alk4 ca      | 50         | 16.0            |
| DE7   | Taram-A wt   | 55         | 0               |
| DE7   | Taram-A ca   | 64         | 45.0            |
| DE7   | Empty vector | 56         | 0               |
| DE14  | None         | 80         | 0               |
| DE14  | Cripto wt    | 54         | 94.4            |
| DE14  | Taram-A wt   | 50         | 1.9             |
| DE14  | Taram-A ca   | 51         | 62.2            |
| DE14  | Empty vector | 60         | 0               |

The data are representative of at least two independent experiments.

DE7 and DE14 are two independent *Cripto*<sup>-/-</sup> clones (see Materials and Methods).

Table 2. Percentage of beating EBs from transfected *Cripto*<sup>-/-</sup> ES cells.

| Construct    | Protein | EBs scored | % of beating EB |
|--------------|---------|------------|-----------------|
| Alk4 ca      | None    | 50         | 16.0            |
| Alk4 ca      | Cripto* | 87         | 87.3            |
| Empty vector | None    | 49         | 0               |
| Empty vector | Cripto* | 60         | 96.6            |

\*Two-day-old EBs treated with 10 µg/ml of recombinant *Cripto* for 3 days.

Table 3. Percentage of beating EBs from *Cripto*<sup>-/-</sup> ES cells transfected with *Cripto* wt or *Cripto* mutant derivatives.

| Cells | Construct | EBs scored | % of beating EBs |
|-------|-----------|------------|------------------|
| DE7   | None      | 97         | 0                |
| DE7   | Cripto wt | 56         | 98.2             |
| DE7   | N63I      | 54         | 91.5             |
| DE7   | G71N      | 54         | 0                |

|      |              |     |      |
|------|--------------|-----|------|
| DE7  | T72A         | 62  | 90.3 |
| DE7  | S77A         | 60  | 95.0 |
| DE7  | F78A         | 47  | 42.5 |
| DE7  | F78W         | 60  | 95.0 |
| DE7  | H104A        | 56  | 89.3 |
| DE7  | W107G        | 57  | 7.6  |
| DE7  | R116G        | 49  | 80.0 |
| DE7  | L122N        | 103 | 92.0 |
| DE7  | Empty vector | 65  | 0    |
| DE14 | None         | 85  | 0    |
| DE14 | Cripto wt    | 54  | 94.4 |
| DE14 | G71N         | 49  | 0    |
| DE14 | F78A         | 45  | 66.0 |
| DE14 | W107G        | 57  | 30.5 |
| DE14 | Empty vector | 71  | 0    |

---

The data are representative of at least two independent experiments.

DE7 and DE14 are two independent *Cripto*<sup>-/-</sup> clones (see Materials and Methods).

---

#### *Cripto*<sup>-/-</sup> ES cells differentiate into neurons without inductive stimulation

When plated on an adhesive substrate, the *Cripto*<sup>-/-</sup> EBs showed the presence of a dense cell network with a morphology like that of neurons. This characteristic morphology is never found in wild type EBs or in *Cripto*<sup>-/-</sup> EBs where *Cripto* signaling was rescued by adding recombinant protein or by transfection with a *Cripto* expression vector. To confirm that the cells were effectively neurons, immunofluorescence assays were performed on *Cripto*<sup>-/-</sup> EBs treated or untreated with recombinant secreted *Cripto* using antibodies that recognize a neuron-specific form of the protein  $\beta$ III-tubulin. This antibody identifies cell groups positive to EBs derived from *Cripto*<sup>-/-</sup> ES cells not treated with *Cripto* protein, thus demonstrating that they are effectively neurons (Figure 8A). Moreover, 70% of *Cripto*<sup>-/-</sup> EBs scored showed cells positive to the isotype III anti- $\beta$ -tubulin antibody, indicating the presence of an elevated percentage of neurons. Cells positive to the isotype III anti- $\beta$ -tubulin antibody are completely absent in *Cripto*<sup>-/-</sup> EBs treated with *Cripto* protein which, in contrast, showed an ample area of cells positive to

the MF-20 antibody that recognizes sarcomeric myosin and was utilized to visualize the cardiomyocytes (Figure 8). These data indicate that the absence of Cripto in ES cells causes the spontaneous differentiation of neurons without inductive stimuli.

To modulate Cripto signaling, the protein was added at various time points during differentiation of EBs derived from Cripto<sup>-/-</sup> ES cells. The addition of Cripto during the 0--2-day window of differentiation again promoted cardiomyocyte differentiation, while dramatically reducing the number of EBs displaying neurons, indicating that the rescue of Cripto signaling inhibits the ability of EBs to spontaneously differentiate into neurons. In contrast, the addition of Cripto during a different time window (3--6 days) did not rescue the cardiac phenotype of Cripto<sup>-/-</sup> ES cells nor did it alter the ability of the cells to spontaneously differentiate into neurons, as indicated by the high percentage of EBs demonstrating the presence of neurons and the absence of cardiomyocytes.

These results indicate that Cripto signaling in a narrow, very early time window (0--2 days) of differentiation inhibits neural differentiation of ES cells and primes them for cardiac differentiation.

#### Nodal antagonists inhibit Cripto activity in cardiomyogenesis

To have direct proof that the Nodal signal is effectively needed for Cripto-regulated induction of ES cells toward the cardiac lineage, we investigated whether Nodal inhibition could interfere with the ability of Cripto to prime cardiomyogenesis. Cripto<sup>-/-</sup> ES cells were transfected with expression vectors for Cerberus, a known Nodal antagonist protein (Piccolo et al., 1999), before treating EBs derived from recombinant Cripto. This multifunctional antagonist inhibits Nodal similarly to BMP and Wnt signaling. A truncated form of Cerberus, Cerberus-Short (CerS), is a specific antagonist only against Nodal (Piccolo et al., 1999). The expression of Cerberus and Cerberus-S significantly inhibits Cripto activity (Table 4). These results show that Cerberus and Cerberus-S can act as effective antagonists against Cripto signaling in ES cell differentiation, confirming the functional role of the Nodal pathway in Cripto-mediated induction of the cardiac lineage.

Table 4. Percentage of beating EBs from Cripto<sup>-/-</sup> ES cells transfected with Nodal antagonists.

| Construct    | Protein             | EBs scored | % of beating EB |
|--------------|---------------------|------------|-----------------|
| Empty vector | None                | 40         | 0               |
| Empty vector | Cripto <sup>a</sup> | 58         | 85              |

|            |                     |    |      |
|------------|---------------------|----|------|
| Cerberus   | None                | 34 | 0    |
| Cerberus   | Cripto <sup>a</sup> | 49 | 10.3 |
| Cerberus-S | None                | 36 | 0    |
| Cerberus-S | Cripto <sup>a</sup> | 40 | 8.3  |

---

<sup>a</sup>Two-day-old EBs treated with 10 µg/ml of recombinant Cripto for 3 days.

---

### References

- Adamson, E.D., Minchiotti, G., and Salomon, D.S. (2002). *J. Cell. Physiol.* **190**, 267-278.
- 5 – Arenas E. (2002). *Mol Cell Neurosci* **21**(2): 205-202.
- Bianco, C., et al. (2002). *Mol. Cell. Biol.* **22**, 2586-2597.
- Bianco, C., et al. (1999). *J. Biol. Chem.* **274**, 8624-8629.
- Brivanlou, A.H., F.H. et al. 2003. *Science*. **300**:913-6.
- Bjorklund L.M., et al. (2002). *PNAS* **99**: 2344-2349.
- 10 – Boheler, K.R., et al. (2002). *Circ. Res.* **91**, 189-201.
- Chang, H., et al. (1999) *Development* **126**, 1631-1642.
- Cheng, S.K., et al. (2003). *Genes Dev.* **17**, 31-36.
- Ciccodicola, A., et al. (1989). *EMBO J.* **8**: 1987-1991
- David, N.B., and Rosa, F.M. (2001). *Development* **128**, 3937-3947.
- 15 – Ding, J., et al. (1998). *Nature* **395**, 702-707.
- Doetschman, T., et al. (1993). *Hypertension* **22**, 618-629.
- Dono, R., et al. (1993). *Development* **118**, 1157-1168.
- Fishman, M.C., and Chien, K.R. (1997). *Development* **124**, 2099-2117.
- Galvin, K.M., et al. (2000). *Nat. Genet.* **24**, 171-174.
- 20 – Gepstein, L. (2002). *Circ. Res.* **91**, 866-876.
- Gritsman, K., et al. (1999). *Cell* **97**, 121-132.
- Hara A, et al. (2004). *Brain Res.* **5**, 216-21.
- Hynes, M., and A. Rosenthal. 2000. *Neuron*. **28**:11-4.
- Keller, G.M. (1995). *Curr. Opin. Cell. Biol.* **7**, 862-869.
- 25 – Laemmli, U.K. (1970). *Nature* **227**, 680-685.
- Liu, S., Y. et al. 2000. *Proc Natl Acad Sci U S A.* **97**:6126-31.
- Lohmeyer, M., et al. (1997). *Biochemistry* **36**, 3837-3845.

- Maglione, D., et al. (1991). *Proc. Natl. Acad. Sci. USA* 88, 9267-9271.
- Maltsev, V.A., et al. (1993). *Mechanism of Development* 44, 41-50.
- Marvin, M.J., et al. (2001). *Genes Dev.* 15, 316-327.
- McFadden, D.G., and Olson, E.N. (2002). *Current Opinon in Genetics and*  
5 *Development* 12, 328-335.
- Min, J.Y., et al. 2002. *J Appl Physiol.* 92:288-96.
- Minchiotti, G., et al. (2001). *Development* 128, 4501-4510.
- Minchiotti, G., Parisi, S., Liguori, G., Signore, M., Lania, G., Adamson, E.D., Lago, C.T., and Persico, M.G. (2000). *Mech. Dev.* 90, 133-142.
- 10 - Monzen, K., et al. (2001). *J. Cell Biol.* 153, 687-698.
- Monzen, K., Nagai, R., and Komuro, I. (2002). *Trends Cardiovasc. Med.* 12, 263.
- Nagy A, et al. *Proc Natl Acad Sci USA* (1993) Sep 15;90(18):8424-8.
- Niwa, H., Yamamura, K., and Miyazaki, J. (1991). *Gene* 108, 193-199.
- Olson, E.N., and Srivastava, D. (1996). *Science* 272, 671-676.
- 15 - Piccolo, S., et al. (1999). *Nature.* 397:707-10.
- Reissmann, E., et al. (2001). *Genes Dev.* 15, 2010-2022.
- Reiter, J.F., Verkade, H., and Stainier, D.Y. (2001). *Dev. Biol.* 234, 330-338.
- Renucci, A., Lemarchandel, V., and Rosa, F. (1996). *Development* 122, 3735-3743.
- Rosa, F.M. (2002). *Sci. STKE* 2002, PE47
- 20 - Rosenthal, N., and Xavier-Neto, J. (2000). *Curr. Opin. Cell Biol.* 12, 742-746.
- Salomon, D.S., Bianco, C., and De Santis, M. (1999). *Bioessays* 21, 61-70.
- Schiffer, S.G., et al. (2001). *J. Biol. Chem.* 276, 37769-37778.
- Schultheiss, T.M., Burch, J.B., and Lassar, A.B. (1997). *Genes Dev.* 11, 451-462.
- Shen, M.M., and Schier, A.F. (2000). *Trends Genet.* 16, 303-309.
- 25 - Smith T.A. and Hooper M.C. (1983). *Exp Cell Res* 145: 458-62.
- Soprano, D.R., and K.J. Soprano. 1995. *Annu Rev Nutr.* 15:111-32.
- Sucov, H.M., and R.M. Evans. 1995. *Mol Neurobiol.* 10:169-84.
- Svendsen, C.N., and A.G. Smith. 1999. *Trends Neurosci.* 22:357-64.
- Tzahor, E., and Lassar, A.B. (2001). *Genes Dev.* 15, 255-260.
- 30 - Wieser, R., Wrana, J.L., and Massague, J. (1995). *EMBO J.* 14, 2199-2208.
- Wobus, A.M., Wallukat, G., and Hesheler, J. (1991). *Differentiation* 48, 173-182.
- Xu, C., et al. (1998). *Dev. Biol.* 196, 237-247.



- Xu, C., et al. (1999). *Development* 126, 483-494.
- Yan, Y.T., et al. (2002). *Mol. Cell. Biol.* 22, 4439-4449.
- Yeo, C., and Whitman, M. (2001). *Mol. Cell* 7, 949-957.

## CLAIMS

1. A method to induce stem cell differentiation in cardiomyocytes, wherein the cells are exposed for a period of time and in effective amounts to a protein of the EGF-CFC family or its derivatives, which comprises at least the EGF and CFC domains.  
5
2. A method according to Claim 1 in which the EGF and CFC domains derive from the sequence of the Cripto protein.
3. A method according to Claim 2 in which the EGF and CFC domains derive from the sequence of human Cripto protein.
- 10 4. A method according to Claim 2 in which the EGF and CFC domains derive from the sequence of mouse Cripto protein.
5. A method according to one of the preceding claims in which cell exposure occurs through genetic expression in stem cells via a suitable vector.
6. Stem cells induced to differentiate into cardiomyocytes obtainable according to the method of one of previous claims.  
15
7. A composition for the treatment of heart diseases that comprises stem cells treated according to Claim 6.
8. The use of the stem cells according to Claim 6 for the treatment of heart diseases.
- 20 9. A composition for therapeutic use for treating heart disorders that comprises a therapeutically effective amount of a protein or its derivative, having at least the EGF and CFC domains of a protein of the EGF-CFC family.
10. A composition according to Claim 9 in which the protein has at least the EGF and CFC domains of the Cripto protein.
- 25 11. A composition according to Claim 9 in which the EGF and CFC domains derive from the human Cripto protein sequence.
12. A composition according to Claim 9 in which the EGF and CFC domains derive from the mouse Cripto protein sequence.
- 30 13. A method to induce stem cell differentiation into neuronal cells, wherein the cells are exposed for a period of time and in effective amounts to an inhibitor of the Cripto protein or the engineering of the cells in such a manner that they do not express endogenous functioning Cripto.

14. A method according to Claim 13 in which exposure to a Cripto inhibitor occurs in the early phases of stem cell differentiation.
15. A method according to Claim 13 in which the Cripto protein inhibitor is an anti-Cripto antibody or functional fragments thereof.
- 5 16. A method according to Claim 13 in which the Cripto protein inhibitor is a peptide specifically selected from a random combinatorial peptide library.
17. A method according to Claim 13 in which the Cripto protein inhibitor is an antagonist of the Alq4(receptor)-Cripto(co-receptor)-Nodal(ligand) pathway.
18. A method according to Claim 17 in which the antagonist is the peptide Cerberus  
10 or its functional derivatives.
19. Stem cells induced to differentiate into neuronal cell lineages obtained according to one of the claims from 13 to 18.
20. A composition for the treatment of neuropathologies that comprises the stem cells according to Claim 19.
- 15 21. The use of the stem cells according to Claim 19 for treating neuropathologies.
22. The use of the Cripto protein or its inhibitors in the preparation of a composition able to direct stem cell differentiation toward the neuronal lineage.




Fig. 1




Fig. 2

2/8




Fig. 3

4/8





Fig. 4




Fig. 5









Fig. 6



A

- Cripto



+ Cripto





Fig. 8

B



(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
30 September 2004 (30.09.2004)

PCT

(10) International Publication Number  
**WO 2004/083375 A3**

(51) International Patent Classification<sup>7</sup>: **C12N 5/06**,  
A61K 35/34, 38/18, A61P 9/00, A61K 39/395, 35/30,  
A61P 25/28

(21) International Application Number:  
PCT/IT2004/000133

(22) International Filing Date: 19 March 2004 (19.03.2004)

(25) Filing Language: Italian

(26) Publication Language: English

(30) Priority Data:  
RM2003A000125 21 March 2003 (21.03.2003) IT  
RM2003A000370 29 July 2003 (29.07.2003) IT

(71) Applicants and

(72) Inventors: **MINCHIOTTI, Gabriella** [IT/IT]; Via Ugo Ricci, 19, I-80100 Napoli (IT). **PERSICO, Maria** [IT/IT]; Via Camillo De Nardis, 10, I-80127 Napoli (IT). **PARISI, Silvia** [IT/IT]; Via Roma, 136, I-80027 Napoli (IT).

(74) Agents: **CAPASSO, Olga** et al.; De Simone & Partners S.p.A., Via Vincenzo Bellini, 20, I-00198 Roma (IT).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
28 October 2004

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHODS OF PROMOTING THE DIFFERENTIATION OF STEM CELLS

(57) Abstract: A method is described by which stem cells are induced to differentiate into cardiomyocytes; the method comprises exposure for a length of time and at efficacious quantities of a protein of the EGF-CFC family or its derivatives having at least the EGF and CFC domains; or to differentiate into neuronal cells, comprising the exposure to Cripto protein inhibitors. Compositions are described for therapeutic use in treating heart disorders, comprising a therapeutically efficacious quantity of a protein or its derivatives having at least the EGF and CFC domains of a protein of the EGF-CFC family.



WO 2004/083375 A3

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT2004/000133

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N5/06 A61K35/34 A61K38/18 A61P9/00 A61K39/395  
A61K35/30 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | XU CHUNHUI ET AL: "Specific arrest of cardiogenesis in cultured embryonic stem cells lacking Cripto-1"<br>DEVELOPMENTAL BIOLOGY,<br>vol. 196, no. 2,<br>15 April 1998 (1998-04-15), pages 237-247,<br>XP002294486<br>ISSN: 0012-1606<br>cited in the application<br>the whole document | 1-12                  |
| X          | WO 01/68814 A (FIELD LOREN J ; ADVANCED RES & TECH INST (US))<br>20 September 2001 (2001-09-20)<br>examples<br>-----<br>-/--   | 6-8                   |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

2 September 2004

Date of mailing of the international search report

17/09/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Teyssier, B

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT2004/000133

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| A          | ADAMSON E D ET AL: "Cripto: A tumor growth factor and more"<br>JOURNAL OF CELLULAR PHYSIOLOGY,<br>vol. 190, no. 3, March 2002 (2002-03),<br>pages 267-278, XP002294487<br>ISSN: 0021-9541<br>cited in the application   |                       |
| X          | WO 02/26941 A (KOOY DEREK V D ; TROPEPE VINCENT (US)) 4 April 2002 (2002-04-04)<br>page 34, line 4 - line 31  | 13-22                 |
| E          | WO 2004/053084 A (MCLEAN HOSPITAL CORP)<br>24 June 2004 (2004-06-24)<br>page 5, line 5 - line 8<br>page 43 - page 48  | 13-22                 |
| A          | PICCOLO S ET AL: "The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals"<br>NATURE,<br>vol. 397, no. 6721,<br>25 February 1999 (1999-02-25), pages<br>707-710, XP002294488<br>ISSN: 0028-0836<br>cited in the application   |                       |
| A          | BALDASSARRE G ET AL: "Transfection with a cripto anti-sense plasmid suppresses endogenous cripto expression and inhibits transformation in a human embryonal carcinoma cell line"<br>INTERNATIONAL JOURNAL OF CANCER,<br>vol. 66, no. 4, 16 May 1996 (1996-05-16),<br>pages 538-543, XP008006513<br>ISSN: 0020-7136 |                       |
| X,P        | PARISI S ET AL: "Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells."<br>JOURNAL OF CELL BIOLOGY,<br>vol. 163, no. 2,<br>27 October 2003 (2003-10-27), pages<br>303-314, XP002294489<br>ISSN: 0021-9525<br>the whole document                         | 1-22                  |

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/IT2004/000133

**Box No. I**      **Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)**

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
  - a. type of material
    - ☒ a sequence listing
    - ☐ table(s) related to the sequence listing
  - b. format of material
    - ☒ in written format
    - ☒ in computer readable form
  - c. time of filing/furnishing
    - ☐ contained in the international application as filed
    - ☐ filed together with the international application in computer readable form
    - ☒ furnished subsequently to this Authority for the purpose of search
2. ☒ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IT2004/000133

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-12

Method to induce stem cell differentiation into cardiomyocytes using a protein of the EGF-CF family; differentiated stem cells, composition and use thereof. A composition for treating heart disorders comprising a protein of the EGF-CF family.

---

2. claims: 13-22

Method to induce stem cell differentiation into neuronal cells using a Cripto inhibitor; differentiated stem cells, composition and use thereof.

---

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

IT/IT2004/000133

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---|---------------------|----------------------------|---------------------|
| WO 0168814                                | A | 20-09-2001          | AU 4355101 A               | 24-09-2001          |
|   |   |                     | CA 2402245 A1              | 20-09-2001          |
|   |   |                     | EP 1265987 A2              | 18-12-2002          |
|   |   |                     | JP 2004504807 T            | 19-02-2004          |
|   |   |                     | WO 0168814 A2              | 20-09-2001          |
| WO 0226941                                | A | 04-04-2002          | AU 9358601 A               | 08-04-2002          |
|   |   |                     | WO 0226941 A2              | 04-04-2002          |
|   |   |                     | CA 2424062 A1              | 04-04-2002          |
|   |   |                     | US 2002164791 A1           | 07-11-2002          |
| WO 2004053084                             | A | 24-06-2004          | WO 2004053084 A2           | 24-06-2004          |

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**